CPTAC

The National Cancer Institute's Clinical Proteomic Tumor Analysis Consortium has publicly released its first proteomic data set.

Broad Institute researchers have devised a method for serial enrichment and analysis of protein post-translational modifications.

In March 2010, Austin, Texas-based diagnostics firm Vermillion launched sales of its OVA1 ovarian cancer test.

The National Cancer Institute last week announced a memorandum of understanding with Seoul National University Cancer Hospital under which SNUCH will test proteomic technologies, standards, workflows, and assays developed by NCI's Clinical Proteomic Tumor Analysis Consortium, CPT

The developers of the ProteoWizard proteomics software platform announced this week that the software now allows sharing and integration of mass spectrometry data across all vendor formats.

A recent investigation by the National Cancer Institute's Cancer Genome Atlas consortium into the genetic underpinnings of breast tumors also offers a glimpse of the benefits of including proteomic data in such analyses.

With proteomics researchers from around the globe gathered in Boston last week for the Human Proteome Organization's 11th annual meeting, scientists and officials from the National Cancer Institute's Clinical Proteomic Tumor Analysis Consortium offered an update on the

The National Cancer Institute's Small Business Innovation Research Development Center this week announced $10 million in new contract funding opportunities, including several for proteomics research reagents.

The question of proteomics' place in the larger world of life science research drove discussion this week at the Human Proteome Organization's 11th annual meeting in Boston as researchers gathered to report on the field's progression and potential as well as the obstac

VANCOUVER, BC – At the American Society for Mass Spectrometry annual meeting here this week a number of major vendors reiterated their commitment to moving their instruments into the clinic (